Phio Pharmaceuticals Corp. (NASDAQ:PHIO) Short Interest Update

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) was the recipient of a significant decrease in short interest in the month of February. As of February 15th, there was short interest totalling 45,500 shares, a decrease of 54.3% from the January 31st total of 99,600 shares. Based on an average trading volume of 6,070,000 shares, the short-interest ratio is presently 0.0 days. Approximately 1.1% of the shares of the stock are short sold.

Phio Pharmaceuticals Price Performance

Shares of PHIO stock traded down $0.01 during mid-day trading on Friday, hitting $1.42. The company had a trading volume of 94,555 shares, compared to its average volume of 9,623,802. The stock’s 50 day moving average price is $2.11 and its 200-day moving average price is $2.62. Phio Pharmaceuticals has a 52-week low of $1.36 and a 52-week high of $10.35. The company has a market capitalization of $9.78 million, a P/E ratio of -0.13 and a beta of 1.53.

Institutional Trading of Phio Pharmaceuticals

A hedge fund recently bought a new stake in Phio Pharmaceuticals stock. Virtu Financial LLC bought a new position in Phio Pharmaceuticals Corp. (NASDAQ:PHIO) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 40,910 shares of the company’s stock, valued at approximately $74,000. Virtu Financial LLC owned about 0.59% of Phio Pharmaceuticals at the end of the most recent quarter. Institutional investors own 57.31% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $4.00 target price on shares of Phio Pharmaceuticals in a research note on Wednesday, February 19th.

About Phio Pharmaceuticals

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.